Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete | Latest News RSS feed

Farxiga Significantly Reduced Hospitalization For Heart Failure Or Cv Death In A Broad Patient Population With Type 2 Diabete - Latest News


First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

Heart failure is one of the most common early cardiovascular complications of type 2 ... that FARXIGA significantly reduced the risk of the composite of hHF or CV death compared to placebo, ... read more

AZ backs diabetes drug Farxiga with new cardio analysis

There were fewer major adverse cardiovascular events observed with Farxiga in the broad patient population ... Farxiga consistently reduced hospitalisation for heart failure across a broad range of ... read more

Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis

RELATED: Lilly's Jardiance snags FDA approval for reducing CV risk in Type 2 ... failure, McDermott said. The results show a classwide effect on heart failure and mortality, not only in patients at ... read more

Looking for another news?


First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

We now have new evidence from DECLARE-TIMI 58 that shows FARXIGA consistently reduced hospitalization for heart failure across a broad range of patients with type 2 ... CV death compared to placebo, ... read more


First sub-analyses from the DECLARE-TIMI 58 trial further support the cardiovascular effects of Farxiga in type-2 diabetes

Dr. Stephen Wiviott of Brigham and Women’s Hospital ... 58 that shows Farxiga consistently reduced hospitalisation for heart failure across a broad range of patients with type-2 diabetes, regardless ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us